

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

**1. (original)** A screening method of a substance that inhibits interaction between anti-troponin I antibody and cardiac troponin I, which comprises measuring and evaluating the inhibitory activity of a test substance on interaction between anti-cardiac troponin I antibody and cardiac troponin I after contacting the anti-cardiac troponin I antibody, the cardiac troponin I and the test substance.

**2. (original)** A screening method of a substance that inhibits the effect of anti-troponin I to a target tissue, which comprises measuring and evaluating the inhibitory activity of a test substance on the effect of anti-cardiac troponin I antibody on a target tissue after contacting the anti-cardiac troponin I, the target tissue and the test substance.

**3. (original)** The screening method according to claim 2, wherein the target tissue is a myocardial cell.

**4. (original)** A pharmaceutical composition of therapy for cardiac disease which is made by steps comprising a step of selecting a substance with activity by the screening method according to any one of claims 1 to 3, a step of manufacturing the above selected substance, and

a step of mixing the substance manufactured by the above described step with a pharmaceutically acceptable solvent for formulation.

**5. (previously presented).** A method for treating cardiac disease, which comprises administering to a subject in need thereof an effective amount of at least one selected from cardiac troponin I protein, a partial protein thereof, and a modified protein thereof.

**6. (previously presented).** The pharmaceutical composition of therapy for cardiac disease according to claim 4, wherein the cardiac disease is dilated cardiomyopathy.

**7. (previously presented).** A therapeutic base material for cardiac disease coupled with a substance selected by the method according to any one of claims 1 to 3 or at least one selected from cardiac troponin I, its partial protein, and a modified protein thereof.

**Claim 8. (Canceled).**

**9. (previously presented).** The therapeutic base material for cardiac disease according to claim 7, wherein the cardiac disease is dilated cardiomyopathy.

**10. (previously presented).** An apparatus for therapy of cardiac disease, which comprises a plasma separating apparatus; an extracorporeal immunity absorbing apparatus that

contacts between separated plasma and the therapeutic base material for cardiac disease according to claim 7; and a reflux apparatus which mixes plasma treated with the above described extracorporeal immunity absorbing apparatus into separated hemocytes, and send it back into body again.

**11. (original)** The apparatus for therapy of cardiac disease according to claim 10, wherein the cardiac disease is a dilated cardiomyopathy.

**12. (original).** A method for making an animal model for evaluating cardiac disease, which comprises administering the anti-cardiac troponin I antibody.

**13. (original).** The method for making an animal model for evaluation of cardiac disease according to claim 12, wherein the cardiac disease is dilated cardiomyopathy.

**14. (original).** A method of screening a substance for therapy of cardiac disease, which comprises determining the effect of a test substance to cardiac disease after administration of the substance to an animal made by the method according to claim 12.

**15 (original).** A method of screening a substance for therapy of dilated cardiomyopathy, which comprises determining the effect of a test substance to cardiac disease after administration of the substance to an animal made by the method according to claim 13.

**16. (previously presented).** A method for treating dilated cardiomyopathy, which comprises administering to a subject in need thereof a substance that inhibits the production of anti-cardiac troponin I autoantibody.

**17. (original).** A diagnosis method of dilated cardiomyopathy, which comprises measuring an amount of anti-cardiac troponin I autoantibody.

**18. (previously presented).** A method for treating for cardiac disease, which comprises administering to a subject in need thereof an effective amount of the pharmaceutical composition according to claim 4.

**19. (previously presented).** The method according to claim 5 or 18, wherein the cardiac disease is dilated cardiomyopathy.

**20. (new)** A method for treating dilated cardiomyopathy, which comprises removing anti-cardiac troponin I autoantibody from a patient's blood.